Investor Presentation Full Year 2017 slide image

Investor Presentation Full Year 2017

Investor Presentation Full year 2017 Slide 91 Global haemophilia market is growing by high-single digit Sales of recombinant coagulation factors Recombinate®/Advate® Strategic positioning of Novo Nordisk's haemophilia portfolio NovoSevenⓇ Coagil VII® KogenateⓇ/HelixateⓇ Idelvion® RixubisⓇ Novo Nordisk compound Status Strategic position ObizurⓇ1 35 XynthaⓇ/RefactoⓇ Eloctate® NovoEight® AlprolixⓇ Benefix® NovoSevenⓇ Launched Maintain market leadership DKK 30 billion NovoEight® Launched 25 Establish presence in a competitive market place 20 N8-GP Phase 33 Contribute to market conversion 15 CAGR²: 4% CAGR²: 10% CAGR²: 16% 10 RefixiaⓇ/ REBINYN® Approved 4 Contribute to new treatment paradigm 5 NovoThirteenⓇ Launched Launch first recombinant product 0 2011 2016 rFVIIa 2011 2016 2011 2016 rFVIII rFIX 1 ObizurⓇ only indicated for acquired haemophilia 2 CAGR for 5-year period changing diabetes® 3 Submission of N8-GP expected Q1 2018 in the US and the EU 4 Refixia® is the brand name for N9-GP in the EU, and REBINYN® is the brand name in the US novo nordisk
View entire presentation